Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06OQI
|
||||
| Former ID |
DIB015151
|
||||
| Drug Name |
Tilarginine acetate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myocardial infarction [ICD9: 410; ICD10:I21, I22] | Phase 3 | [521644] | ||
| Company |
ArgiNOx
|
||||
| Formula |
C9H20N4O4
|
||||
| Canonical SMILES |
CNC(=N)NCCC[C@H](N)C(=O)O.CC(=O)O
|
||||
| InChI |
1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1
|
||||
| InChIKey |
IKPNWIGTWUZCKM-JEDNCBNOSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, endothelial | Target Info | Modulator | [528757] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| NetPath Pathway | Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Thromboxane A2 receptor signaling | |||||
| SHP2 signaling | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| PAR1-mediated thrombin signaling events | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.